CIK 0001649989
- Non-accelerated filer
- Smaller reporting company
Outlook Therapeutics, Inc.
Sign in to watch- Ticker
- OTLK
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 383982704
- Phone
- +1 609-619-3990
- Business address
- 111 S. WOOD AVENUE, UNIT #100, ISELIN, NJ, 08830
- Former names
- Oncobiologics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-11-07 | BioLexis Pte Ltd. Director | Grant or award | +8,577,248 | $0.93 | $8.0M | 52,904,631 |
| 2018-10-22 | Bahrt Kenneth Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +450,000 | 450,000 | ||
| 2018-10-22 | MCANDREW STEPHEN J SVP Bus. Strat. & Dev. | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2018-09-30 | BioLexis Pte Ltd. Director | Other acquisition · Series A-1 Convertible Preferred Stock | +1,468 | 60,203 | ||
| 2018-09-30 | BioLexis Pte Ltd. 10% owner | Other acquisition · Series A-1 Convertible Preferred Stock | +1,648 | 60,383 | ||
| 2018-09-21 | THURMAN RANDY H Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-09-21 | HILZINGER KURT J Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-09-21 | Windisch Joerg Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-09-21 | Mohan Pankaj Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2018-09-18 | KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy | Sale | −10,100 | $0.87 | $9K | 57,213 |
| 2018-08-01 | KENYON LAWRENCE A CEO, Pres, CFO, Treas & Secy | Grant or award · Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2018-07-18 | GMS Tenshi Holdings Pte. Ltd Director | Grant or award · Series A Convertible Preferred Stock | +6,526 | 58,735 | ||
| 2018-07-18 | GMS Tenshi Holdings Pte. Ltd Director | Returned to the company · Series A Convertible Preferred Stock | −58,735 | 0 | ||
| 2018-07-18 | GMS Tenshi Holdings Pte. Ltd Director | Grant or award · Series A-1 Convertible Preferred Stock | +58,735 | 58,735 | ||
| 2018-06-27 | THURMAN RANDY H Director | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2018-06-25 | Bahrt Kenneth Chief Medical Officer | Sale | −7,700 | $0.85 | $7K | 47,120 |
| 2018-06-20 | GMS Tenshi Holdings Pte. Ltd Director | Conversion | +31,572,617 | 44,327,383 | ||
| 2018-06-20 | GMS Tenshi Holdings Pte. Ltd Director | Conversion · Series A Convertible Preferred Stock | −208,836 | 52,209 | ||
| 2018-06-15 | MCANDREW STEPHEN J SVP Bus. Strat. & Dev. | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2018-06-08 | GMS Tenshi Holdings Pte. Ltd Director | Grant or award | +6,377,383 | $0.98 | $6.2M | 12,754,766 |
Page 16 of 20 · 386 trades